Page 1 de 61 résultats
FIELD OF THE INVENTION
The present invention relates generally to a method for noninvasive treatment of diabetic retinopathy. More so, the present invention relates to a method that prevents and reverses diabetic retinopathy and other vascular retinopathies using a series of non-invasive light and
CROSS-REFERENCE TO RELATED APPLICATIONS
This is the U.S. national stage of International Patent Application No. PCT/CN2016/098510, filed on Sep. 9, 2016, which claims the benefit of priority from Chinese Patent Application No. 201510573355.4, filed on Sep. 10, 2015. The entire contents of both of
FIELD OF THE INVENTION
The present invention relates generally to compositions and methods for regulating one or more isoforms of protein kinase C. In particular embodiments, the present invention relates to compositions and methods for treating conditions associated with excessive permeability of
BACKGROUND OF THE INVENTION
The invention relates to methods for treating plasma kallikrein-related disorders, such as diseases or conditions associated with increased vascular permeability or astrocyte activation. Such diseases include diabetic retinopathy, macular edema, intracerebral hemorrhage,
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein
R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl,
R.sub.b
The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them.
More particularly the present invention provides a compound of formula I
##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b
FIELD OF THE INVENTION
The present invention relates to the field of interfering RNA compositions for inhibition of expression of hypoxia-inducible factor-1.alpha. (HIF-1.alpha.), the protein encoded by HIF1A mRNA, in ocular angiogenesis, including those cellular changes resulting from the
BACKGROUND
Therapeutic lasers are often used to treat various conditions of the eye. For example, a specific type of condition that may be treated with such lasers is diabetic retinopathy. Diabetic retinopathy, is damage to the retina that is due to complications of diabetes. If left untreated,
BACKGROUND
Therapeutic lasers are often used to treat various conditions of the eye. For example, a specific type of condition that may be treated with such lasers is diabetic retinopathy. Diabetic retinopathy, is damage to the retina that is due to complications of diabetes. If left untreated,
BACKGROUND
Therapeutic lasers are often used to treat various conditions of the eye. For example, a specific type of condition that may be treated with such lasers is diabetic retinopathy. Diabetic retinopathy, is damage to the retina that is due to complications of diabetes. If left untreated,
BACKGROUND
Therapeutic lasers are often used to treat various conditions of the eye. For example, a specific type of condition that may be treated with such lasers is diabetic retinopathy. Diabetic retinopathy, is damage to the retina that is due to complications of diabetes. If left untreated,
BACKGROUND
Therapeutic lasers are often used to treat various conditions of the eye. For example, a specific type of condition that may be treated with such lasers is diabetic retinopathy. Diabetic retinopathy, is damage to the retina that is due to complications of diabetes. If left untreated,
BACKGROUND
Therapeutic lasers are often used to treat various conditions of the eye. For example, a specific type of condition that may be treated with such lasers is diabetic retinopathy. Diabetic retinopathy, is damage to the retina that is due to complications of diabetes. If left untreated,
NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT
Not Applicable.
BACKGROUND OF THE INVENTION
Field of the Invention
The present disclosure relates generally to the fields of molecular biology and virology, and in particular, to the development of gene delivery vehicles. Disclosed are improved